Acromegaly Update

Surgical technique innovation and a JCEM editorial from two giants of the field reshape how we think about curing GH-secreting tumors and managing cancer risk in acromegaly, while the rare disease sector sees a burst of late-stage deal-making and pla... more

A landmark JCEM special issue lands this week with five major reviews and original studies that collectively reset the clinical playbook for acromegaly — from emerging oral therapies to the underappreciated mortality burden — while in the rare diseas... more

New Pituitary research this week highlights the cardiac and bone risks that persist even in treated acromegaly patients, while the rare disease industry grapples with a mixed regulatory environment — one notable ASCO data release and continued fallou... more

A network meta-analysis confirms that injectable somatostatin receptor ligands remain first-line in acromegaly, while new clinical data on paltusotine and pasireotide, plus rare disease industry news including BioMarin and Intellia, shape the week.

New proteomic biomarkers could sharpen acromegaly diagnosis beyond GH/IGF-1, while the rare disease industry sees a wave of FDA decisions and high-stakes M&A activity.

Acromegaly research this week centered on the long-term pharmacology of established therapies and clinical management updates, while the rare disease industry absorbed significant regulatory and pipeline news.

A quiet week on the acromegaly research front (one letter-to-editor only) is more than offset by a loud week in the wider rare-disease industry — capped by Angelini's $4.1B takeout of Catalyst, an FDA reversal that revives Atara and Pierre Fabre's ra... more

This week's literature brings a long-term safety confirmation for pegvisomant monotherapy, a head-to-head comparison of first-generation somatostatin analogs using a validated composite score, and new evidence linking acromegaly to hepatic steatosis ... more